期刊
ONCOGENE
卷 30, 期 9, 页码 1046-1058出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.488
关键词
endoglin; CD105; breast cancer; TGF-beta; MCF10A; ErbB2
资金
- Breakthrough Breast Cancer
- NHS
- Marie Curie Intra-European Fellowship [PIEF-GA-2008-221083]
- Breast Cancer Research Scotland
- Tayside Tissue Bank
Tumor growth factor-beta (TGF-beta) signaling in cancer has been implicated in growth suppression of early lesions and enhancing tumor cell invasion and metastasis. However, the cellular mechanisms that determine this signaling output in individual tumors are still largely unknown. In endothelial cells, TGF-beta signaling is modulated by the TGF-beta co-receptor endoglin (CD105). Here we demonstrate that endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. Endoglin downregulation in non-tumorigenic MCF10A breast cells leads to the formation of abnormal acini in 3D culture, but does not promote cell migration or transformation. In contrast, in the presence of activated ErbB2, endoglin downregulation in MCF10A cells leads to enhanced invasion into a 3D matrix. Consistent with these data, ectopic expression of endoglin in MDA-MB-231 cells blocks TGF-beta-enhanced cell motility and invasion and reduces lung colonization in an in vivo metastasis model. Unlike endothelial cells, endoglin does not modulate Smad-mediated TGF-beta signaling in breast cells but attenuates the cytoskeletal remodeling to impair cell migration and invasion. Importantly, in a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. Oncogene (2011) 30, 1046-1058; doi:10.1038/onc.2010.488; published online 1 November 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据